Why It Matters
Private equity involvement in healthcare has drawn heightened regulatory attention across the country as states move to restrict acquisitions and require greater transparency. The wave of state-level restrictions is reshaping deal economics and timelines for healthcare investors, signaling a fundamental shift in how lawmakers oversee a sector that has become a major target for financial buyers.
What Happened
The volume and value of private equity healthcare transactions have declined sharply as state legislatures impose new restrictions on deal-making. Deal values in the first half of 2026 fell compared to the same period in 2025, marking a reversal of the healthcare sector’s role as a consistent acquisition target for investors.
At least 25 states have either proposed or enacted laws designed to increase oversight of healthcare transactions. Three states—California, Oregon, and Rhode Island—implemented new regulations requiring documentation and transparency requirements for healthcare mergers and acquisitions in 2026. Seven additional states, including Indiana, Massachusetts, Maine, New Mexico, and Washington, enacted private equity healthcare laws during 2025. Connecticut passed legislation in 2026 focused on accountability and transparency for private equity-owned nursing homes.
Six more states—Hawaii, Indiana, New York, Pennsylvania, Vermont, and Virginia—introduced bills in 2026 that would either expand transaction oversight or limit private equity operations in healthcare. These statutes and proposed measures have extended approval timelines and increased compliance costs, making acquisitions more complicated and expensive for private equity firms.
Rhode Island’s regulatory framework exemplifies the transparency-focused approach. Rhode Island Attorney General Peter Neronha characterized the state’s stance, saying “private equity and increasing market consolidation drive up the cost of care, further inhibiting patient access.” The state’s law is intended to provide “a bird’s eye view to ensure that future medical group mergers do not harm Rhode Islanders’ access to health care services,” Neronha added, as first reported by the New Jersey Monitor.
By the Numbers
At least 25 states — proposed or passed healthcare transaction oversight laws
Seven states — enacted private equity healthcare laws in 2025
Approximately 50% — projected decline in physician practice management deals in 2026 compared to 2025
$1 trillion — private equity healthcare acquisitions over the past decade
11% — increase in nursing home death rate linked to private equity ownership (2023 study)
Approximately 90% — financially stressed healthcare companies owned by private equity (2022 Moody’s report)
Zoom Out
Private equity’s entry into healthcare accelerated dramatically over the past decade, with firms investing roughly $1 trillion in acquisitions across the sector. The strategy focused on cost reduction and operational efficiency often produced scrutiny when acquisitions involved nursing homes and physician practices. A 2023 study found private equity involvement correlated with an 11 percent increase in nursing home mortality rates. A 2022 Moody’s analysis documented that nearly 90 percent of financially distressed healthcare companies were owned by private equity firms.
The state-by-state regulatory response reflects growing concern among lawmakers and healthcare advocates about consolidation’s effects on access and quality. Other sectors have experienced similar private equity-driven consolidation, but healthcare’s direct connection to mortality, care access, and public health has made it a particular focus for legislative restraint.
What’s Next
The regulatory landscape will likely continue to fragment as more states enact transaction oversight measures and transparency requirements. Private equity firms will need to adapt deal structures and timelines to accommodate state-level approval processes. Whether the declining deal volume reflects permanent market retreat or temporary adjustment to new regulatory costs remains unclear, but the trajectory suggests that state regulation is reshaping healthcare deal economics for the foreseeable future.